This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
by Zacks Equity Research
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHRS) Outperforming Other Medical Stocks This Year?
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CHRS) Outperforming Other Medical Stocks This Year?
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
by Zacks Equity Research
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
Pulmatrix Surges on License Agreement With Johnson & Johnson
by Zacks Equity Research
Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.
Arena (ARNA) Expands Strategic Deal With Beacon Discovery
by Zacks Equity Research
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
by Zacks Equity Research
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHRS) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Top Ranked Momentum Stocks to Buy for December 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd
Top Ranked Momentum Stocks to Buy for November 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 26th
Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline
by Zacks Equity Research
Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors Can Find Strong Stocks with our First Profit Screen
by Benjamin Rains
Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...
Coherus BioSciences (CHRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors Can Find Big Returns with this First Profit Screen
by Benjamin Rains
We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...
Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?